Technology evaluation: CV-787, Calydon Inc

Current Opinion in Molecular Therapeutics

Volumn 3, Issue 2, 2001, Pages 204-210

  Doehn, C ^a   Jocham, D ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABARELIX; ANTIANDROGEN; ANTINEOPLASTIC AGENT; BICALUTAMIDE; BUSERELIN; CV 787; CYPROTERONE ACETATE; DOCETAXEL; ESTROGEN; FLUTAMIDE; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GOSERELIN; IMMUNOSUPPRESSIVE AGENT; LEUPRORELIN; NILUTAMIDE; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; STEROID; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADENOVIRUS; ARTICLE; CANCER CELL; CELL DESTRUCTION; CELL KILLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ENHANCER REGION; EVALUATION; GENE TARGETING; GENETIC ENGINEERING; HUMAN; INJECTION PAIN; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; MOUSE; MULTICENTER STUDY; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROSTATE CANCER; TECHNOLOGY; UNITED STATES; UNIVERSITY HOSPITAL; VIRUS ATTENUATION; VIRUS RECOMBINANT; VIRUS REPLICATION;

ADENOVIRUSES, HUMAN; ANIMALS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; ENHANCER ELEMENTS (GENETICS); GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; MALE; MULTICENTER STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP;

ADENOVIRIDAE; ARCA;

EID: 0035028269     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy
2. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells
3. Replicating vectors for gene therapy of cancer: Risks, limitations and prospects
4. Gene therapy - Promises, problems and prospects
5. Prostate tumor-specific cytolysis and tumor eradication by intravenous administration of CN787, and attenuated replication competent adenovirus containing E3
6. Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer
7. Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs
8. Gene therapy - The future is here: A guide to the practicing urologist
9. Management of hormone refractory prostate cancer: Current standards and future prospects
10. An analysis of watchful waiting for clinically localized prostate cancer
11. In situ gene therapy for adenocarcinoma of the prostate: A phase I clinical trial
12. Gene therapy for prostate cancer: New perspectives on an old problem
13. Gene therapy of prostate cancer: p53, suicidal genes, and other targets
14. Clinical application for gene therapy in prostate cancer
15. Training viruses to attack cancers
16. Molecular and clinical activity of CN706, a PSA selective oncolytic Ad5 vector in a phase I trial in locally recurrent prostate cancer following radiation therapy
17. The natural history of early prostate cancer and the impact of endocrine treatment
18. Maximum androgen blockade in advanced prostate cancer: A meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens
19. Estrogens in the treatment of prostate cancer
20. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer
21. Maximal androgen blockade: Final analysis of EORTC phase III trial 30853
22. Hormonal therapy in the management of prostate cancer: From Huggins to the present
23. Some aspects of the biology and endocrinology of prostate cancer
24. Evaluation and management of the man who has failed primary curative therapy for prostate cancer
25. Hormone and antihormone withdrawal: Implications for the management of androgen-independent prostate cancer
26. Controversies in the management of advanced prostate cancer
27. Immune responses to adenoviruses: Viral evasion mechanisms and their implications for the clinic
28. Cell proliferation, DNA repair and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation
29. Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: Implications and proposals for human therapy
30. Bioactivity of CN706, a PSA specific oncolytic adenoviral vector: A phase I trial of in vivo gene therapy for locally-recurrent prostate cancer following radiation therapy
31. Results of a phase I study of CN706, a replication-competent cytolytic adenovirus, for the treatment of adenocarcinoma of the prostate which is locally-recurrent following radiation therapy
32. Gene therapy for prostate cancer: Where are we now?
33. Methods of gene delivery
34. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration
35. Advances in adenoviral vectors: From genetic engineering to their biology
36. Development and application of adenoviral vectors for gene therapy of cancer
37. Treatment options after failure of local curative treatments in prostate cancer: A controversial issue
38. The addition of adenovirus type 5 region E3 enables Calydon virus 787 to eliminate distant prostate tumor xenografts
39. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel